Related Experiment Videos
Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus
K Furukawa1, H Sasaki, R B Pollard
1The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA.
Abstract:
The protective effect of a new antifungal compound, lanoconazole, against Cryptococcus neoformans infection in C57BL/6 mice exposed to LP-BM5 murine leukaemia virus (MuLV) (MAIDS mice) was investigated. Mice were infected intratracheally with C. neoformans, strain 613D, 40 days after infection with LP-BM5 MuLV. They were treated orally with various doses of lanoconazole or with fluconazole 10 mg/kg (a positive control) once daily beginning 1 day after the fungal infection and continuing until the end of the experimental period. The number of C. neoformans cells in the lungs and brains of infected mice was determined. Lanoconazole and fluconazole had a similar inhibitory effect on the growth of C. neoformans in the brains and lungs of normal mice. Whereas lanoconazole inhibited the growth of C. neoformans in the brains and lungs of MAIDS mice, the pathogen grew in the brains of MAIDS mice treated with fluconazole. Lanoconazole reduced the number of C. neoformans in the brains of normal mice treated with a type 2 cytokine mixture, whereas fluconazole did not. A predominance of type 2 T-cell responses was demonstrated in MAIDS mice. Splenic T cells from MAIDS mice, but not those from normal mice, released interleukins 4 and 10 into the culture medium when they were stimulated with an anti-CD3 monoclonal antibody. These results suggest that lanoconazole may have the potential to inhibit the growth of C. neoformans in AIDS patients with a predominance of type 2 T-cell responses.
Insights
Lanoconazole effectively inhibited Cryptococcus neoformans growth in MAIDS mice, unlike fluconazole. This new antifungal shows promise for treating fungal infections in immunocompromised individuals with specific immune responses.
Area of Science:
- Mycology
- Immunology
- Pharmacology
Background:
- Cryptococcus neoformans is an opportunistic fungal pathogen causing severe infections, particularly in immunocompromised individuals.
- Murine Acquired Immunodeficiency Syndrome (MAIDS) mice exhibit a type 2 T-cell response, mimicking aspects of human immunodeficiency.
- Existing antifungal therapies like fluconazole may be less effective in certain immunocompromised states.
Purpose of the Study:
- To investigate the efficacy of a novel antifungal compound, lanoconazole, against Cryptococcus neoformans infection in a MAIDS mouse model.
- To compare the protective effects of lanoconazole with fluconazole in both normal and MAIDS mice.
- To explore the influence of lanoconazole on C. neoformans growth in the context of type 2 T-cell responses.
Main Methods:
- C57BL/6 mice were infected with LP-BM5 murine leukemia virus (MuLV) to induce MAIDS.
- Mice were intratracheally infected with Cryptococcus neoformans and subsequently treated with varying doses of lanoconazole or fluconazole.
- Fungal burden in lungs and brains was quantified; splenic T-cell cytokine production (IL-4, IL-10) was measured.
Main Results:
- Lanoconazole and fluconazole demonstrated similar antifungal activity in normal mice.
- Lanoconazole significantly inhibited C. neoformans growth in the lungs and brains of MAIDS mice, whereas fluconazole showed limited efficacy.
- Lanoconazole reduced fungal burden in normal mice treated with a type 2 cytokine mixture, unlike fluconazole.
Conclusions:
- Lanoconazole exhibits superior efficacy over fluconazole in controlling Cryptococcus neoformans infection in an immunocompromised MAIDS mouse model.
- The antifungal activity of lanoconazole appears effective even in the presence of a type 2 T-cell-dominant immune response.
- Lanoconazole holds potential as a therapeutic agent for Cryptococcus neoformans infections in immunocompromised patients, including those with AIDS and type 2 immune skewing.